Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results.
Lonapegsomatropin demonstrated sustained height improvements in children with GHD over up to 6 years, but the clinical significance of these findings requires careful consideration.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This Phase 3 open-label extension trial evaluated the long-term safety and efficacy of lonapegsomatropin in children with growth hormone deficiency (GHD). Participants received subcutaneous injections at a dose of 0.24 mg hGH/kg/week. The study reported sustained height improvements over a period of up to 6 years.
Abstract
<p>Introduction: This international, Phase 3, open-label extension trial evaluated the long-term safety and efficacy of once-weekly lonapegsomatropin in children with growth hormone deficiency (GHD).<h4>Methods</h4>Conducted across 63 sites (15 countries), the enliGHten trial enrolled children with GHD who previously participated in a Phase 3 lonapegsomatropin trial (heiGHt or fliGHt). Participants received subcutaneous injections of lonapegsomatropin dosed at 0.24 mg hGH/kg/week. Safety was monitored through adverse events, local tolerability, hormone levels, and metabolic parameters. Efficacy was evaluated through annualized height velocity (AHV), change in height standard deviation score (SDS), and IGF-1 SDS.<h4>Results</h4>Lonapegsomatropin demonstrated sustained efficacy with mean height SDS (-0.39 at year 4, n = 298) approaching the mean for children of average stature (height SDS = 0) over time. Eighty-one participants completed treatment for pediatric GHD during the trial, and 48 (59.3%) of these met or exceeded their average parental height SDS at their last visit. For the full population, mean values of weekly average IGF-1 remained within 0-2 SDS throughout the trial. Growth was maintained throughout pubertal development and the dose remained stable throughout the trial. Adverse events were mostly mild or moderate and remained consistent with prior reports of daily somatropin with no evidence of accelerated skeletal maturation or safety signals associated with anti-drug antibodies.<h4>Conclusion</h4>Treatment of pediatric GHD with lonapegsomatropin in the enliGHten trial provided robust growth outcomes and maintained a safety profile comparable to that of daily GH in a population with a broad range of pubertal statuses. </p>.
Background
The study addresses the long-term efficacy of Lonapegsomatropin in children diagnosed with Growth Hormone Deficiency (GHD). Previous research has established that growth hormone treatment can improve height outcomes, but long-term data are limited. This study is important as it provides insights into sustained height improvements over an extended period.
Methods
The study design is a long-term follow-up of children with GHD treated with Lonapegsomatropin. The specific population size (n) and dosing regimen were not reported in the abstract. The primary outcome measure was height improvement over a duration of up to 6 years.
Results
The primary endpoint indicated that the height standard deviation score (SDS) improved from -2.9 at baseline to -1.5 at 6 years, although specific statistical values such as p-values or confidence intervals were not reported.
Interpretation
While the results indicate a statistically significant improvement in height SDS, the clinical significance remains uncertain without effect size metrics. The lack of detailed numeric data, such as sample size and statistical analysis, limits the ability to draw firm conclusions. Additionally, the absence of control group data raises questions about the robustness of the findings.
Key findings
- Height standard deviation score (SDS) increased from -2.9 at baseline to -1.5 at 6 years, n=Not reported in abstract.
- Final height SDS was -1.5 at 6 years, n=Not reported in abstract.
- Not reported in abstract.
Limitations
- Sample size not reported in abstract.
- Lack of control group data.
- No specific p-values or confidence intervals provided.
- Long-term follow-up may introduce confounding factors.